Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database.
Scanvion Q, Béné J, Gautier S, Grandvuillemin A, Le Beller C, Chenaf C, Etienne N, Brousseau S, Cortot AB, Mortier L, Staumont-Sallé D, Morschhauser F, Forestier A, Groh M, Launay D, Hachulla E, Labalette M, Kahn JE, Lefèvre G. Scanvion Q, et al. Oncoimmunology. 2020 Apr 7;9(1):1722022. doi: 10.1080/2162402X.2020.1722022. eCollection 2020. Oncoimmunology. 2020. PMID: 32313716 Free PMC article.
First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.
Durrieu G, Palmaro A, Pourcel L, Caillet C, Faucher A, Jacquet A, Ouaret S, Perault-Pochat MC, Kreft-Jais C, Castot A, Lapeyre-Mestre M, Montastruc JL; French Network of Pharmacovigilance Centres. Durrieu G, et al. Drug Saf. 2012 Oct 1;35(10):845-54. doi: 10.1007/BF03261980. Drug Saf. 2012. PMID: 22967189
Safety surveillance of influenza A(H1N1)v monovalent vaccines during the 2009-2010 mass vaccination campaign in France.
Caillet C, Durrieu G, Jacquet A, Faucher A, Ouaret S, Perrault-Pochat MC, Kreft-Jaïs C, Castot A, Montastruc JL; French Network of Pharmacovigilance Centres. Caillet C, et al. Eur J Clin Pharmacol. 2011 Jun;67(6):649-51. doi: 10.1007/s00228-010-0961-8. Epub 2010 Dec 14. Eur J Clin Pharmacol. 2011. PMID: 21153631 No abstract available.
DPP4 inhibitor-induced polyarthritis: a report of three cases.
Crickx E, Marroun I, Veyrie C, Le Beller C, Schoindre Y, Bouilloud F, Blétry O, Kahn JE. Crickx E, et al. Rheumatol Int. 2014 Feb;34(2):291-2. doi: 10.1007/s00296-013-2710-7. Epub 2013 Mar 5. Rheumatol Int. 2014. PMID: 23462883
Poly(ADP-ribose)polymerase inhibitors-associated myeloid neoplasms: a retrospective study from the French Network of Pharmacovigilance centres.
Morice PM, Genthon A, Boyer T, Bihan K, Mahé J, Sourisseau A, Peyrouzet H, Miremont G, Lepelley M, Stefani L, Gaboriau L, Rocher F, Aquaronne D, Le Beller C, Allouchery M, Azzouz B, Massy N, Alt-Tebacher M, Simand C, Herbrecht R, Chrétien B, Dolladille C, Chantepie S, Alexandre J. Morice PM, et al. Br J Haematol. 2022 Feb;196(3):787-793. doi: 10.1111/bjh.17863. Epub 2021 Oct 5. Br J Haematol. 2022. PMID: 34611896 No abstract available.
40 results